[Bencyclane in the therapy of diseases of motor organs].
D001341:Autonomic Nervous System / Q000187:drug effects; D003508:Cycloheptanes / Q000009:adverse effects / Q000627:therapeutic use*; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D009124:Muscle Proteins; D009132:Muscles / Q000187:drug effects; D009135:Muscular Diseases / Q000188:drug therapy*; D010146:Pain / Q000150:complications; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014666:Vasomotor System / Q000187:drug effects
D003508:Cycloheptanes; D005650:Fumarates; D009124:Muscle Proteins; D010276:Parasympatholytics; D011437:Propylamines; D014665:Vasodilator Agents
Die Anwendung von Bencyclan bei Erkrankungen der Bewegungsorgane.